Reference

Preparation of cyclic imides as inhibitors of tumor necrosis factor a

Preparation of cyclic imides as inhibitors of tumor necrosis factor a. Muller, George W. (Celgene Corporation, USA). U.S. US 5605914 A 25 Feb 1997, 22 pp., Cont.-in-part of U.S. Ser. No. 87,510, abandoned. (English). (United States of America). CODEN: USXXAM. CLASS: ICM: C07D209-48. ICS: A61K031-40. NCL: 514339000. APPLICATION: US 1994-258587 10 Jun 1994. PRIORITY: US 1993-87510 2 Jul 1993; US 1993-140237 20 Oct 1993. There are some commonly used reagents like 187839-05-0 in this article. DOCUMENT TYPE: Patent CA Section: 27 (Heterocyclic Compounds (One Hetero Atom)) Section cross-reference(s): 1, 34, 63 Cyclic imides, such as I [R5 = H, NO2, CN, CF3, CO2Et, CO2Me, CO2Pr, Ac, CONH2, AcO, CO2H, OH, NH2, alkyl, alkoxy, halo; R7 = pyridyl, substituted Ph, (un)substituted benzyl, naphthyl, benzyloxy, imidazol-4-ylmethyl; R12 = amino, OH, ester; n = 0-3 ], are inhibitors of tumor necrosis factor a and can be used to combat cachexia, endotoxic shock, and retrovirus replication. Thus, I (R5 = H, R7 = 4-MeOC6H4, R12 = NH2, n = 1) was prepd. from 3-(4-MeOC6H4)CH(NH2)CH2CO2H and N-(carboethoxy)phthalimide via amidation of the phthalimidopropionic acid. Also, 2-(2,6-dioxo-3-piperidinyl)-4-azaisoindoline-1,3-dione (II) was prepd. from L-glutamine and 2,3-pyridinedicarboxylic anhydride via intramol. cyclization of glutaramic acid III. .